Catheter Precision SEC Filings

Catheter Precision, Inc. investor Joseph Reda filed a Schedule 13G reporting a significant ownership position in the company’s common stock. He beneficially owns 176,674 shares, representing 7.5% of the outstanding common stock, with sole voting and dispositive power over all these shares.

The 7.5% figure is based on 2,357,127 Catheter Precision common shares outstanding as verified with the issuer on February 11, 2026. Reda certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Catheter Precision.

Catheter Precision, Inc. entered into a complex private placement financing involving common stock and multiple new series of convertible preferred stock to raise capital and restructure its balance sheet. The initial closing covers 392,608 common shares at $1.43 each and 1,616.33 shares of Series C-1 preferred, initially convertible into up to 1,130,301 common shares, for total gross proceeds of $2,177,759.00.

Investors also committed to additional Series C-2 and C-3 preferred purchases and obtained an option to buy up to $39,233,333 of Series C-4 preferred, all with conversion prices tied to future trading levels and subject to a floor that the company may waive. Net proceeds will be used to repay debt, fund general corporate needs, and unwind or restructure the legacy catheter business while simplifying liabilities and operating costs.

Separately, the company agreed to acquire 19.98% of Fly Flyte, Inc. from SEG Jets LLC in exchange for 5,250 shares of Series D preferred, valuing the stake at $5.25 million. A registration rights agreement requires Catheter Precision to register resales of common stock underlying the new preferred series. A letter agreement with existing Series B preferred and warrant holders lowers exercise and conversion prices to $1.78 per share, generating $400,621.04 in warrant exercise proceeds and converting Series B into common stock equal to 9.99% of outstanding shares immediately after conversion.

Catheter Precision, Inc. Chairman and CEO David A. Jenkins reported derivative holdings in Series M Common Stock Purchase Warrants. On December 31, 2025, he reported 170,000 Series M warrants at an exercise price of $1.56 per underlying common share held directly, and another 170,000 Series M warrants at the same exercise price held indirectly.

The warrants are initially exercisable any time on or after the stockholder approval date, and each warrant terminates on the five and one half year anniversary of its initial exercise date. The indirect position is associated with FatBoy Capital LP, whose general partner is SeaCap Management LLC, where Mr. Jenkins serves as managing member.

Catheter Precision, Inc. extended the maturities of several 8% Short Term Promissory Notes held by entities associated with its executive chair and CEO, David A. Jenkins. On December 31, 2025, the company entered into Second Amendments to these notes, moving their maturity dates from January 31, 2026 to January 31, 2028 for a $500,000 note held by Jenkins Family Charitable Institute and to January 31, 2029 for notes with principal amounts of $500,000, $150,000, $250,000 and $100,000 held by Mr. Jenkins and FatBoy Capital, L.P.

The filing highlights that Mr. Jenkins is the managing member of the general partner of FatBoy Capital and the settlor of the Jenkins Family Charitable Institute, and that he and his affiliates also hold stock options and rights to receive 11.77% royalties on net sales of the LockeT device. The amendments are treated as a material definitive agreement and a direct financial obligation for the company.

Catheter Precision, Inc. director James J. Caruso reported a small equity transaction in the company’s stock. On 12/05/2025, he acquired 41 shares of common stock at a price of $0 per share in a transaction coded “C,” indicating a conversion. Following this transaction, he directly beneficially owned 50 shares of common stock.

The filing also shows activity in Series X Convertible Preferred Stock, with a conversion price of $0. On the same date, 7.932 shares of this preferred stock were involved in a transaction coded “C,” with no common shares shown as underlying afterward and 0 derivative securities beneficially owned. The accompanying note explains that the Series X Convertible Preferred Stock has no expiration date.

Catheter Precision, Inc. reported an insider stock transaction by its Chairman and CEO, David A. Jenkins. On 12/05/2025, Jenkins converted shares of Series X Convertible Preferred Stock into common stock at a stated price of $0 per share. Following these conversions, he directly held 13,799 common shares, with an additional 34,579 shares held indirectly through a partnership and 109 shares held indirectly through a charitable remainder unitrust. The filing notes that the preferred stock has no expiration date and that some of the indirectly held shares are controlled via entities managed by Jenkins or his spouse, clarifying the structure of his beneficial ownership.

Catheter Precision, Inc. reported that it has given notice to terminate its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., which supported its at-the-market equity offering program. The termination is scheduled to be effective on November 24, 2025.

The program allowed the company to offer and sell shares of common stock with an aggregate offering price of up to $4.3 million. Before issuing the termination notice, Catheter Precision sold approximately $4.0 million of common stock under this program, and it will not owe any termination penalties.

Catheter Precision, Inc. (VTAK) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The company provided this update under Item 2.02 of the Exchange Act.

The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under Section 18. VTAK’s common stock trades on NYSE American.

Catheter Precision, Inc. reported Q3 2025 results showing small but growing sales and ongoing losses, alongside a going concern warning. Revenue was $226,000 for the quarter (vs. $96,000 a year ago) and $581,000 for the nine months (vs. $271,000). Net loss attributable to the company was $2.251 million in Q3 and $11.405 million year to date.

Cash and cash equivalents were $1.075 million as of September 30, 2025, with a working capital deficit of $2.9 million and accumulated deficit of $303.8 million. Total liabilities were $19.0 million, including royalties payable due to related parties of $10.743 million. Management states there is substantial doubt about the ability to continue as a going concern.

To fund operations, the company completed a private placement on May 12, 2025 collecting $1.5 million in cash plus QHSLab notes, and sold 868,582 shares under an ATM launched May 19, 2025 for gross proceeds of $4.0 million. A 1‑for‑19 reverse stock split became effective on August 15, 2025. Shares outstanding were 1,668,375 as of November 7, 2025.